Genentech, Protein Design Settle Patent License Dispute

Law360, New York (December 22, 2003, 12:00 AM EST) -- Genentech Inc. and Protein Design Labs Inc. finalized their settlement over their license dispute concerning antibodies related to three drugs, the two companies said.

Under the terms of the settlement, Genentech will pay Protein Design Labs reduced royalty fees for asthma drug Xolair, psoriasis drug Raptiva and Avastin, an experimental colon-cancer drug that is expected to be approved by the U.S. Food and Drug Administration early next year.

The specific terms of the deal were not disclosed.

Genentech said it will pay licensing fees to Protein...
To view the full article, register now.